These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9297729)

  • 1. Pharmacoeconomics and therapeutic drug monitoring.
    Bootman JL; Harrison DL
    Pharm World Sci; 1997 Aug; 19(4):178-81. PubMed ID: 9297729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic series: Part I. Pharmacoeconomics and the evaluation of drugs and services.
    McGhan WF
    Hosp Formul; 1993 Apr; 28(4):365-6, 371-3, 377-8. PubMed ID: 10125323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ECONOMIC ISSUES IN THERAPEUTIC DRUG MONITORING.
    Petryszyn P; Wiela-Hojeńska A
    Acta Pol Pharm; 2016; 73(3):599-604. PubMed ID: 27476276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of therapeutic drug monitoring in pharmacoeconomics.
    Destache CJ
    Ther Drug Monit; 1993 Dec; 15(6):608-10. PubMed ID: 8122303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt.
    Elsisi GH; Kaló Z; Eldessouki R; Elmahdawy MD; Saad A; Ragab S; Elshalakani AM; Abaza S
    Value Health Reg Issues; 2013; 2(2):319-327. PubMed ID: 29702884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom.
    Kanavos P; Trueman P; Bosilevac A
    Int J Technol Assess Health Care; 2000; 16(4):1179-92. PubMed ID: 11155837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Providing cost-effective therapy using pharmacoeconomic evaluations: the public sector approach.
    Finder S
    Clin Ther; 1997; 19(1):160-6. PubMed ID: 9182021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions.
    Tonin FS; Aznar-Lou I; Pontinha VM; Pontarolo R; Fernandez-Llimos F
    Pharm Pract (Granada); 2021; 19(1):2302. PubMed ID: 33727994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the pharmacoeconomics of pharmaceutical care.
    Plumridge RJ; Wojnar-Horton RE
    Pharmacoeconomics; 1998 Aug; 14(2):175-89. PubMed ID: 10186458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.
    Reeder CE
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S5-8. PubMed ID: 8846244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does expenditure on pharmaceuticals give good value for money?: current evidence and policy implications.
    Coyle D; Drummond M
    Health Policy; 1993 Nov; 26(1):55-75. PubMed ID: 10130847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value for money in the health sector: the contribution of primary health care.
    Mills A; Drummond M
    Health Policy Plan; 1987 Jun; 2(2):107-28. PubMed ID: 10312103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Evaluation of Hospital and Community Pharmacy Services.
    Gammie T; Vogler S; Babar ZU
    Ann Pharmacother; 2017 Jan; 51(1):54-65. PubMed ID: 27586430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategic planning for applied pharmacoeconomics programs.
    Wanke LA; Ryan GM
    Pharm Pract Manag Q; 1996 Jan; 15(4):64-74. PubMed ID: 10153846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-benefit analysis of drug treatment services: review of the literature*.
    Cartwright WS
    J Ment Health Policy Econ; 2000 Mar; 3(1):11-26. PubMed ID: 11967433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs, innovation and efficiency in anti-infective therapy.
    Bootman JL; Milne RJ
    Pharmacoeconomics; 1996; 9 Suppl 1():31-9. PubMed ID: 10160114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles of pharmacoeconomic analysis of drug therapy.
    Freund DA; Dittus RS
    Pharmacoeconomics; 1992 Jan; 1(1):20-31. PubMed ID: 10147037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.